Eve & Co Completes Issuance of $550,000 Convertible Debentures

By Dr. Matthew Watson

STRATHROY, Ontario, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce that it has successfully completed its non-brokered financing of unsecured convertible debentures in the principal amount of Cdn$550,000 (the “Debentures”) to certain individuals, including the Company’s Chief Executive Officer, Melinda Rombouts. The proceeds from the Debentures will be utilized for general working capital purposes.

Excerpt from:
Eve & Co Completes Issuance of $550,000 Convertible Debentures

Related Post


categoriaGlobal News Feed commentoComments Off on Eve & Co Completes Issuance of $550,000 Convertible Debentures | dataDecember 14th, 2020

About...

This author published 5872 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024